A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large us cohort

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1472-1481

  Gross, Rachael L ^a   Schwartzman Morris, Julie S ^a   Krathen, Michael ^b   Reed, George ^c   Chang, Hong ^b   Saunders, Katherine C ^d   Fisher, Mark C ^e   Greenberg, Jeffrey D ^f   Putterman, Chaim ^a   Mease, Philip J ^g   Gottlieb, Alice B ^b   Kremer, Joel M ^h   Broder, Anna ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Departments of Biostatistics and Epidemiology and Outcomes Research   (United States)

^e NYU HOSPITAL FOR JOINT DISEASES   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Seattle Rhumatology Associates   (United States)

^h ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE ACTIVITY; DISEASE DURATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYELOMA; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; UNITED STATES;

ADULT; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPHOMA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REGISTRIES; SKIN NEOPLASMS; UNITED STATES;

EID: 84901641866     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38385     Document Type: Article

References (47)

1. Chen YJ, Chang YT, Wang CB, Wu CY,. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum 2011; 63: 352-8.
2. Hakulinen T, Isomaki H, Knekt P,. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985; 78: 29-32.
3. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH,. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A: 1753-7.
4. Thomas E, Brewster DH, Black RJ, Macfarlane GJ,. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497-502.
5. Boffetta P, Gridley G, Lindelof B,. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001; 117: 1531-7.
6. Chen YJ, Wu CY, Chen TJ, Shen JL, Chu SY, Wang CB, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol 2011; 65: 84-91.
7. Olsen JH, Moller H, Frentz G,. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992; 27: 716-22.
8. Frentz G, Olsen JH,. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999; 140: 237-42.
9. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB,. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006; 126: 2194-201.
10. Reddy SM, Anandarajah AP, Fisher MC, Mease PJ, Greenberg JD, Kremer JM, et al. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large US disease registry. J Rheumatol 2010; 37: 2566-72.
11. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
12. Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD,. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008; 58: 82-7.
13. Kremer J,. The CORRONA database. Ann Rheum Dis 2005; 64 Suppl 4: iv37-41.
14. Dreyer L, Mellemkjaer L, Andersen AR, Bennett P, Poulsen UE, Juulsgaard Ellingsen T, et al. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides: a follow-up study from the DANBIO registry. Ann Rheum Dis 2013; 72: 79-82.
15. Wolfe F, Michaud K,. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95.
16. Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR, et al. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord 2012; 13: 85.
17. Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010; 69: 1596-602.
18. Aletaha D, Smolen J,. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 Suppl 39: S100-8.
19. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP,. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346-53.
20. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
21. Cameron AC, Trivedi PK,. Regression analysis of count data. Cambridge, UK: Cambridge University Press; 1998.
22. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
23. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A,. Tumor necrosis factor α drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008; 9: 52.
24. Leombruno JP, Einarson TR, Keystone EC,. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-45.
25. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60: 3180-9.
26. Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 2013; 52: 91-8.
27. Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-904.
28. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM,. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64: 1035-50.
29. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909-15.
30. Georgescu L, Quinn GC, Schwartzman S, Paget SA,. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997; 26: 794-804.
31. Suzuki M, Hirano S, Ito H, Matsubara D, Kubota K, Takeda Y, et al. Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis. Respirology 2007; 12: 774-6.
32. Paul C, Le Tourneau A, Cayuela JM, Devidas A, Robert C, Molinie V, et al. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol 1997; 133: 867-71.
33. Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14: 1943-9.
34. Kremer JM,. Is methotrexate oncogenic in patients with rheumatoid arthritis? Semin Arthritis Rheum 1997; 26: 785-7.
35. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS,. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995; 99: 276-81.
36. Bologna C, Picot MC, Jorgensen C, Viu P, Verdier R, Sany J,. Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Ann Rheum Dis 1997; 56: 97-102.
37. Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008; 59: 794-9.
38. Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2014; 43: 489-97.
39. Bailin PL, Tindall JP, Roenigk HH Jr, Hogan MD,. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA 1975; 232: 359-62.
40. Nyfors A, Jensen H,. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics: a preliminary study. Dermatologica 1983; 167: 260-1.
41. Stern RS,. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006; 142: 1132-5.
42. Husni ME, Mease PJ,. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 2010; 12: 281-7.
43. Athas WF, Hunt WC, Key CR,. Changes in nonmelanoma skin cancer incidence between 1977-1978 and 1998-1999 in Northcentral New Mexico. Cancer Epidemiol Biomarkers Prev 2003; 12: 1105-8.
44. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005; 294: 681-90.
45. Miller DL, Weinstock MA,. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30: 774-8.
46. Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011; 10: 289-300.
47. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012; 308: 898-908.